> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Public Citizen Supplements Olmesartan Petition
- URL: https://www.fdaweb.com/public-citizen-supplements-olmesartan-petition/
- Published: 2018-02-13T12:00:00.000Z
- Updated: 2026-09-14T23:21:59.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5140751

Public Citizen has supplemented its 11/15/17 petition asking FDA to require removal from the market of all medications containing olmesartan medoxomil, an angiotensin II receptor blocker (ARB), due to risk of sprue-like enteropathy. The 2/1 [supplement](https://www.citizen.org/our-work/health-and-safety/supplement-petition-fda-ban-olmesartan-containing-hypertension-medications?ref=fdaweb.com) cites a large cohort [study](http://onlinelibrary.wiley.com/doi/10.1111/apt.14518/full?ref=fdaweb.com) published in *Alimentary Pharmacology and Therapeutics* that it says “provides additional evidence showing that use of olmesartan is associated with a higher rate of sprue-like enteropathy compared with the use of other ARBs. The findings from this study further confirm what FDA knew five years ago: that olmesartan causes sprue-like enteropathy and olmesartan users experience a significantly higher rate of this adverse event than users of other ARBs.”